Medirom Healthcare Technologies Inc. (MRM) intrinsic value & 10-year financials
Medirom Healthcare Technologies Inc. (MRM) has a Graham intrinsic value of ¥947.31 per share. Over the last 7 fiscal years revenue grew 16.2% a year to ¥8.3B, with an average return on invested capital of -17.1%.
- Graham intrinsic value
- ¥947.31
- Revenue (FY2024)
- ¥8.3B
- Revenue growth (7-yr CAGR)
- 16.2%
- ROIC (10-yr avg)
- -17.1%
- Free cash flow (FY2024)
- -¥1.4B
MRM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | ¥8.3B | ¥148.8M | ¥28.52 | -¥1.4B | -0.2% | -0.6% |
| FY2023 | ¥6.8B | ¥115.4M | ¥22.34 | -¥767.6M | -5.7% | -17.9% |
| FY2022 | ¥7.0B | ¥149.0M | ¥27.23 | -¥806.4M | 1.4% | 4.9% |
| FY2021 | ¥5.4B | -¥990.7M | -¥203.13 | -¥652.9M | -8.7% | -39.0% |
| FY2020 | ¥3.3B | -¥539.2M | -¥133.97 | -¥440.0M | -22.3% | -50.9% |
| FY2019 | ¥3.9B | ¥17.3M | ¥4.06 | ¥464.0K | 0.9% | 1.1% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in JPY.
Executive summary
Medirom Healthcare Technologies Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Medirom Healthcare Technologies Inc. has historically struggled to out-earn its cost of capital, averaging just -17.1% ROIC.
Medirom Healthcare Technologies Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Medirom Healthcare Technologies Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $947.31 per share.